{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:43:38Z","timestamp":1790808218317,"version":"4.1.0"},"reference-count":90,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine disorder in women of\nreproductive age. It presents with gynaecologic, metabolic, and psychologic manifestations. The\ndominant drivers of pathophysiology are hyperandrogenism and insulin resistance. Both conditions\nare related to cardiometabolic risk factors, such as obesity, hypertension, dyslipidaemia, hyperglycaemia,\ntype 2 and gestational diabetes, nonalcoholic fatty liver disease and obstructive sleep apnoea.\nWomen with PCOS of reproductive age consistently demonstrated an elevated risk of subclinical\natherosclerosis, as indicated by different measurement methods, while findings for menopausal age\ngroups exhibited mixed results. Translation of subclinical atherosclerosis into the increased incidence\nof peripheral arterial disease and major cardiovascular (CV) events is less clear. Although several\nexpert groups have advised screening, the CV risk assessment and prevention of CV events are frequently\nunderdiagnosed and overlooked aspects of the management of PCOS. A combination of lifestyle\nmanagement and pharmacotherapy, including the promising new era of anti-obesity medicine,\ncan lead to improvements in cardiometabolic health.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115701611269146230920073301","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T06:23:37Z","timestamp":1696227817000},"page":"424-432","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular\nEvents in Polycystic Ovary Syndrome: Time to Implement Systematic\nScreening and Update the Management"],"prefix":"10.2174","volume":"21","author":[{"given":"Andrej","family":"Janez","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana,\nSlovenia"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Herman","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana,\nSlovenia"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Poredos","sequence":"additional","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[{"name":"Division of Surgery and\nInterventional Science, Department of Surgical Biotechnology, University College London Medical School, University\nCollege London (UCL), UK"},{"name":"Department of Clinical Biochemistry, Royal Free Hospital Campus (UCL), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Blinc","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"},{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miso","family":"Sabovic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"},{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katica Bajuk","family":"Studen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"},{"name":"Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateja Kaja","family":"Jezovnik","sequence":"additional","affiliation":[{"name":"Department of Advanced\nCardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston,\nTexas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerit-Holger","family":"Schernthaner","sequence":"additional","affiliation":[{"name":"Division of Angiology, Department of Medicine 2, Division of Angiology, Medical University of Vienna,\nVienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Anagnostis","sequence":"additional","affiliation":[{"name":"Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynaecology, Medical School,\nAristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Antignani","sequence":"additional","affiliation":[{"name":"Vascular Centre Nuova Villa Claudia, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Jensterle","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana,\nSlovenia"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.fertnstert.2022.03.009","volume":"117","author":"Guan C.","year":"2022","unstructured":"Guan C.; Zahid S.; Minhas A.S.; Polycystic ovary syndrome: A \u201crisk-enhancing\u201d factor for cardiovascular disease. Fertil Steril 2022,117(5),924-935","journal-title":"Fertil Steril"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004,19(1),41-47","journal-title":"Hum Reprod"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"dgad463","DOI":"10.1210\/clinem\/dgad463","author":"Teede H.J.","year":"2023","unstructured":"Teede H.J.; Tay C.T.; Laven J.J.E.; Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab 2023,dgad463","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.metabol.2018.11.002","volume":"92","author":"Glueck C.J.","year":"2019","unstructured":"Glueck C.J.; Goldenberg N.; Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism 2019,92,108-120","journal-title":"Metabolism"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/GRF.0000000000000563","volume":"64","author":"Lentscher J.A.","year":"2021","unstructured":"Lentscher J.A.; Decherney A.H.; Clinical presentation and diagnosis of polycystic ovarian syndrome. Clin Obstet Gynecol 2021,64(1),3-11","journal-title":"Clin Obstet Gynecol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/2633494120911038","author":"Louwers Y.V.","year":"2020","unstructured":"Louwers Y.V.; Laven J.S.E.;  Characteristics of polycystic ovary syndrome throughout life 2020,14","journal-title":"Characteristics of polycystic ovary syndrome throughout life"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/cen.13922","volume":"90","author":"Mo L.","year":"2019","unstructured":"Mo L.; Mansfield D.R.; Joham A.; Sleep disturbances in women with and without polycystic ovary syndrome in an Australian National Cohort. Clin Endocrinol 2019,90(4),570-578","journal-title":"Clin Endocrinol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/obr.12762","volume":"20","author":"Lim S.S.","year":"2019","unstructured":"Lim S.S.; Kakoly N.S.; Tan J.W.J.; Metabolic syndrome in polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. Obes Rev 2019,20(2),339-352","journal-title":"Obes Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/liv.14279","volume":"40","author":"Sarkar M.","year":"2020","unstructured":"Sarkar M.; Terrault N.; Chan W.; Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int 2020,40(2),355-359","journal-title":"Liver Int"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/pedi.13206","volume":"22","author":"Hudnut-Beumler J.","year":"2021","unstructured":"Hudnut-Beumler J.; Kaar J.L.; Taylor A.; Development of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity. Pediatr Diabetes 2021,22(5),699-706","journal-title":"Pediatr Diabetes"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e1827","DOI":"10.1210\/clinem\/dgz285","volume":"105","author":"Simon S.","year":"2020","unstructured":"Simon S.; Rahat H.; Carreau A.M.; Poor sleep is related to metabolic syndrome severity in adolescents with pcos and obesity. J Clin Endocrinol Metab 2020,105(4),e1827-e1834","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1055\/s-0032-1328878","volume":"30","author":"Legro R.","year":"2012","unstructured":"Legro R.; Obesity and PCOS: Implications for diagnosis and treatment. Semin Reprod Med 2012,30(6),496-506","journal-title":"Semin Reprod Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2147\/CLEP.S311785","volume":"13","author":"Tao Y.","year":"2021","unstructured":"Tao Y.; Liu B.; Chen Y.; Genetically predicted cigarette smoking in relation to risk of polycystic ovary syndrome. Clin Epidemiol 2021,13,527-532","journal-title":"Clin Epidemiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3109\/09513590.2013.788634","volume":"29","author":"Pau C.T.","year":"2013","unstructured":"Pau C.T.; Keefe C.C.; Welt C.K.; Cigarette smoking, nicotine levels and increased risk for metabolic syndrome in women with polycystic ovary syndrome. Gynecol Endocrinol 2013,29(6),551-555","journal-title":"Gynecol Endocrinol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.fertnstert.2009.03.062","volume":"94","author":"Cupisti S.","year":"2010","unstructured":"Cupisti S.; H\u00e4berle L.; Dittrich R.; Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance. Fertil Steril 2010,94(2),673-677","journal-title":"Fertil Steril"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2337\/dc18-1738","volume":"42","author":"Kakoly N.S.","year":"2019","unstructured":"Kakoly N.S.; Earnest A.; Teede H.J.; Moran L.J.; Joham A.E.; The impact of obesity on the incidence of type 2 diabetes among women with poly-cystic ovary syndrome. Diabetes Care 2019,42(4),560-567","journal-title":"Diabetes Care"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.fertnstert.2010.12.027","volume":"95","author":"Wild RA","year":"2011","unstructured":"Wild RA; Rizzo M; Clifton S; Carmina E; Lipid levels in polycystic ovary syndrome: Systematic review and meta-analysis. Fertil Steril 2011,95(3),1073-1079.e11, 11","journal-title":"Fertil Steril"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2265.1992.tb02295.x","volume":"37","author":"Conway G.S.","year":"1992","unstructured":"Conway G.S.; Agrawal R.; Betteridge D.J.; Jacobs H.S.; Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992,37(2),119-125","journal-title":"Clin Endocrinol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","year":"2002","unstructured":"National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002,106(25),3143-3421","journal-title":"Circulation"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12958-020-00576-1","volume":"18","author":"Amiri M.","year":"2020","unstructured":"Amiri M.; Ramezani Tehrani F.; Behboudi-Gandevani S.; Bidhendi-Yarandi R.; Carmina E.; Risk of hypertension in women with polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol 2020,18(1),23","journal-title":"Reprod Biol Endocrinol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/10641963.2020.1772815","volume":"42","author":"\u00d6zkan S.","year":"1993","unstructured":"\u00d6zkan S.; Y\u0131lmaz \u00d6.\u00c7.; Yavuz B.; Increased masked hypertension prevalence in patients with polycystic ovary syndrome (PCOS). Clin Exp Hypertens 1993,42(8),681-684","journal-title":"Clin Exp Hypertens"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/humupd\/dms030","volume":"18","author":"Lim S.S.","year":"2012","unstructured":"Lim S.S.; Davies M.J.; Norman R.J.; Moran L.J.; Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update 2012,18(6),618-637","journal-title":"Hum Reprod Update"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2217\/WHE.13.53","volume":"9","author":"Yildiz B.O.","year":"2013","unstructured":"Yildiz B.O.; Polycystic ovary syndrome: Is obesity a symptom? Womens Health 2013,9(6),505-507","journal-title":"Womens Health"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2337\/diab.38.9.1165","volume":"38","author":"Dunaif A.","year":"1989","unstructured":"Dunaif A.; Segal K.R.; Futterweit W.; Dobrjansky A.; Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989,38(9),1165-1174","journal-title":"Diabetes"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.tcm.2019.08.010","volume":"30","author":"Osibogun O.","year":"2020","unstructured":"Osibogun O.; Ogunmoroti O.; Michos E.D.; Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc Med 2020,30(7),399-404","journal-title":"Trends Cardiovasc Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"E707","DOI":"10.1152\/ajpendo.00532.2018","volume":"316","author":"Cree-Green M.","year":"2019","unstructured":"Cree-Green M.; Carreau A.M.; Rahat H.; Amino acid and fatty acid metabolomic profile during fasting and hyperinsulinemia in girls with polycystic ovarian syndrome. Am J Physiol Endocrinol Metab 2019,316(5),E707-E718","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.3390\/ijms24043140","volume":"24","author":"Herman R.","year":"2023","unstructured":"Herman R.; Sikonja J.; Jensterle M.; Janez A.; Dolzan V.; Insulin metabolism in polycystic ovary syndrome: Secretion, signaling, and clearance. Int J Mol Sci 2023,24(4),3140","journal-title":"Int J Mol Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"E1047","DOI":"10.1152\/ajpendo.00361.2004","volume":"288","author":"Corbould A.","year":"2005","unstructured":"Corbould A.; Kim Y.B.; Youngren J.F.; Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005,288(5),E1047-E1054","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1016\/S0021-9258(18)69090-8","volume":"263","author":"Takayama S.","year":"1988","unstructured":"Takayama S.; White M.F.; Kahn C.R.; Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988,263(7),3440-3447","journal-title":"J Biol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1210\/jc.2002-020363","volume":"87","author":"Li M.","year":"2002","unstructured":"Li M.; Youngren J.F.; Dunaif A.; Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: Effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab 2002,87(9),4088-4093","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/humrep\/dew243","volume":"31","author":"Cassar S.","year":"2016","unstructured":"Cassar S.; Misso M.L.; Hopkins W.G.; Shaw C.S.; Teede H.J.; Stepto N.K.; Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod 2016,31(11),2619-2631","journal-title":"Hum Reprod"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/humrep\/des463","volume":"28","author":"Stepto N.K.","year":"2013","unstructured":"Stepto N.K.; Cassar S.; Joham A.E.; Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013,28(3),777-784","journal-title":"Hum Reprod"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fendo.2013.00037","volume":"4","author":"Cerf M.E.","year":"2013","unstructured":"Cerf M.E.; Beta cell dysfunction and insulin resistance. Front Endocrinol 2013,4,37","journal-title":"Front Endocrinol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fendo.2018.00384","volume":"9","author":"Oh Y.S.","year":"2018","unstructured":"Oh Y.S.; Bae G.D.; Baek D.J.; Park E.Y.; Jun H.S.; Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front Endocrinol 2018,9,384","journal-title":"Front Endocrinol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1210\/er.2007-0006","volume":"28","author":"Muniyappa R.","year":"2007","unstructured":"Muniyappa R.; Montagnani M.; Koh K.K.; Quon M.J.; Cardiovascular actions of insulin. Endocr Rev 2007,28(5),463-491","journal-title":"Endocr Rev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1210\/jcem.86.10.7904","volume":"86","author":"Diamanti-Kandarakis E.","year":"2001","unstructured":"Diamanti-Kandarakis E.; Spina G.; Kouli C.; Migdalis I.; Increased endothelin-1 levels in women with polycystic ovary syndrome and the bene-ficial effect of metformin therapy. J Clin Endocrinol Metab 2001,86(10),4666-4673","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1758-5996-6-12","volume":"6","author":"Zhou M.S.","year":"2014","unstructured":"Zhou M.S.; Wang A.; Yu H.; Link between insulin resistance and hypertension: What is the evidence from evolutionary biology? Diabetol Metab Syndr 2014,6(1),12","journal-title":"Diabetol Metab Syndr"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ecl.2008.06.001","volume":"37","author":"Muniyappa R.","year":"2008","unstructured":"Muniyappa R.; Iantorno M.; Quon M.J.; An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am ix-x.2008,37(3),685-711","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12958-016-0203-8","volume":"14","author":"Yang R.","year":"2016","unstructured":"Yang R.; Yang S.; Li R.; Liu P.; Qiao J.; Zhang Y.; Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: A meta-analysis. Reprod Biol Endocrinol 2016,14(1),67","journal-title":"Reprod Biol Endocrinol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1530\/EJE-17-0124","volume":"177","author":"Schiffer L.","year":"2017","unstructured":"Schiffer L.; Kempegowda P.; Arlt W.; O\u2019Reilly M.W.; MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. Eur J Endocrinol 2017,177(3),R125-R143","journal-title":"Eur J Endocrinol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1161\/01.CIR.103.10.1410","volume":"103","author":"Paradisi G.","year":"2001","unstructured":"Paradisi G.; Steinberg H.O.; Hempfling A.; Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001,103(10),1410-1415","journal-title":"Circulation"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1210\/jc.85.5.1851","volume":"85","author":"Mather K.J.","year":"2000","unstructured":"Mather K.J.; Verma S.; Corenblum B.; Anderson T.J.; Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2000,85(5),1851-1856","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/00033197211072598","volume":"73","author":"Sun D.","year":"2022","unstructured":"Sun D.; Wu Y.; Ding M.; Zhu F.; Comprehensive meta-analysis of functional and structural markers of subclinical atherosclerosis in women with polycystic ovary syndrome. Angiology 2022,73(7),622-634","journal-title":"Angiology"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1089\/jwh.2021.0608","volume":"31","author":"Osibogun O.","year":"2002","unstructured":"Osibogun O.; Ogunmoroti O.; Kolade O.B.; Hays A.G.; Okunrintemi V.; Minhas A.S.; A systematic review and meta-analysis of the association between polycystic ovary syndrome and coronary artery calcification. J Womens Health 2002,31(6),762-771","journal-title":"J Womens Health"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1093\/humrep\/dem324","volume":"22","author":"Luque-Ram\u00edrez M.","year":"2007","unstructured":"Luque-Ram\u00edrez M.; Mendieta-Azcona C.; Alvarez-Blasco F.; Escobar-Morreale H.F.; Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 2007,22(12),3197-3203","journal-title":"Hum Reprod"},{"key":"ref=46","first-page":"401","volume":"38","author":"Demir B.","year":"2011","unstructured":"Demir B.; Pasa S.; Demir S.; Morphologic and functional vascular alterations in patients with polycystic ovary syndrome. Clin Exp Obstet Gynecol 2011,38(4),401-404","journal-title":"Clin Exp Obstet Gynecol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2004.04.007","volume":"175","author":"Lakhani K.","year":"2004","unstructured":"Lakhani K.; Hardiman P.; Seifalian A.M.; Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004,175(2),353-359","journal-title":"Atherosclerosis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1210\/jcem.87.2.8199","volume":"87","author":"Kelly C.J.G.","year":"2002","unstructured":"Kelly C.J.G.; Speirs A.; Gould G.W.; Petrie J.R.; Lyall H.; Connell J.M.C.; Altered vascular function in young women with polycystic ovary syn-drome. J Clin Endocrinol Metab 2002,87(2),742-746","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/cen.14117","volume":"92","author":"Meun C.","year":"2020","unstructured":"Meun C.; Gunning M.N.; Louwers Y.V.; The cardiovascular risk profile of middle\u2010aged women with polycystic ovary syndrome. Clin Endocrinol 2020,92(2),150-158","journal-title":"Clin Endocrinol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1210\/jc.2012-1690","volume":"97","author":"Morgan C.L.","year":"2012","unstructured":"Morgan C.L.; Jenkins-Jones S.; Currie C.J.; Rees D.A.; Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: A retrospective, observational study. J Clin Endocrinol Metab 2012,97(9),3251-3260","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2265.2010.03907.x","volume":"74","author":"Chang A.Y.","year":"2011","unstructured":"Chang A.Y.; Ayers C.; Minhajuddin A.; Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. Clin Endocrinol 2011,74(1),89-96","journal-title":"Clin Endocrinol"},{"key":"ref=52","first-page":"74","volume":"70","author":"Iftikhar S.","year":"2012","unstructured":"Iftikhar S.; Collazo-Clavell M.L.; Roger V.L.; Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med 2012,70(2),74-80","journal-title":"Neth J Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/09513590.2017.1347779","volume":"33","author":"Zhou Y.","year":"2017","unstructured":"Zhou Y.; Wang X.; Jiang Y.; Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: Insights from a meta-analysis. Gynecol Endocrinol 2017,33(12),904-910","journal-title":"Gynecol Endocrinol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"33715","DOI":"10.18632\/oncotarget.9553","volume":"7","author":"Zhao L.","year":"2016","unstructured":"Zhao L.; Zhu Z.; Lou H.; Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): A meta-analysis. Oncotarget 2016,7(23),33715-33721","journal-title":"Oncotarget"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"552421","DOI":"10.3389\/fcvm.2020.552421","volume":"7","author":"Zhang J.","year":"2020","unstructured":"Zhang J.; Xu J.H.; Qu Q.Q.; Zhong G.Q.; Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: A meta-analysis of cohort studies. Front Cardiovasc Med 2020,7,552421","journal-title":"Front Cardiovasc Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ejendo\/lvad077","volume":"189","author":"Ollila M.M.","year":"2023","unstructured":"Ollila M.M.; Arffman R.K.; Korhonen E.; Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria: A prospective population-based cohort study. Eur J Endocrinol 2023,189(1),96-105","journal-title":"Eur J Endocrinol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"oead061","DOI":"10.1093\/ehjopen\/oead061","volume":"3","author":"Lo ACQ","year":"2023","unstructured":"Lo ACQ; Lo CCW; Oliver-Williams C; Cardiovascular disease risk in women with hyperandrogenism, oligomenorrhea\/menstrual irregularity or polycystic ovaries (components of polycystic ovary syndrome): A systematic review and meta-analysis. Eur Heart J Open 2023,3(4),oead061","journal-title":"Eur Heart J Open"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/ejendo\/lvad067","volume":"188","author":"Dwivedi A.K.","year":"2023","unstructured":"Dwivedi A.K.; Vishwakarma D.; Dubey P.; Reddy S.; Association of polycystic ovary syndrome with cardiovascular disease among female hospitalizations in the United States. Eur J Endocrinol 2023,188(6),555-563","journal-title":"Eur J Endocrinol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/humupd\/dmaa029","volume":"26","author":"Wekker V.","year":"2020","unstructured":"Wekker V.; van Dammen L.; Koning A.; Long-term cardiometabolic disease risk in women with PCOS: A systematic review and meta-analysis. Hum Reprod Update 2020,26(6),942-960","journal-title":"Hum Reprod Update"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01000.x","volume":"52","author":"Wild S.","year":"2000","unstructured":"Wild S.; Pierpoint T.; McKeigue P.; Jacobs H.; Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study. Clin Endocrinol 2000,52(5),595-600","journal-title":"Clin Endocrinol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/cen.12068","volume":"78","author":"Mani H.","year":"2013","unstructured":"Mani H.; Levy M.J.; Davies M.J.; Diabetes and cardiovascular events in women with polycystic ovary syndrome: A 20-year retrospective cohort study. Clin Endocrinol 2013,78(6),926-934","journal-title":"Clin Endocrinol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/humupd\/dmr001","volume":"17","author":"de Groot P.C.M.","year":"2011","unstructured":"de Groot P.C.M.; Dekkers O.M.; Romijn J.A.; Dieben S.W.M.; Helmerhorst F.M.; PCOS, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-analysis. Hum Reprod Update 2011,17(4),495-500","journal-title":"Hum Reprod Update"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12933-018-0680-5","volume":"17","author":"Glintborg D.","year":"2018","unstructured":"Glintborg D.; Rubin K.H.; Nybo M.; Abrahamsen B.; Andersen M.; Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol 2018,17(1),37","journal-title":"Cardiovasc Diabetol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1210\/jc.2014-3886","volume":"100","author":"Hart R.","year":"2015","unstructured":"Hart R.; Doherty D.A.; The potential implications of a PCOS diagnosis on a woman\u2019s long-term health using data linkage. J Clin Endocrinol Metab 2015,100(3),911-919","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1210\/jcem.87.5.8471","volume":"87","author":"Solomon C.G.","year":"2002","unstructured":"Solomon C.G.; Hu F.B.; Dunaif A.; Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002,87(5),2013-2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1210\/jc.2007-0425","volume":"93","author":"Shaw L.J.","year":"2008","unstructured":"Shaw L.J.; Bairey Merz C.N.; Azziz R.; Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women\u2019s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008,93(4),1276-1284","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/GME.0b013e31802cc7ab","volume":"14","author":"Krentz A.J.","year":"2007","unstructured":"Krentz A.J.; von M\u00fchlen D.; Barrett-Connor E.; Searching for polycystic ovary syndrome in postmenopausal women: Evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 2007,14(2),284-292","journal-title":"Menopause"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1089\/jwh.2015.5441","volume":"25","author":"Merz C.N.B.","year":"2002","unstructured":"Merz C.N.B.; Shaw L.J.; Azziz R.; Stanczyk F.Z.; Sopko G.; Braunstein G.D.; Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J Womens Health 2002,25(9),875-881","journal-title":"J Womens Health"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e3369","DOI":"10.1210\/clinem\/dgab392","volume":"106","author":"Berni T.R.","year":"2021","unstructured":"Berni T.R.; Morgan C.L.; Rees D.A.; Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: A population study. J Clin Endocrinol Metab 2021,106(9),e3369-e3380","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/0003319711436248","volume":"64","author":"Dogan M.I.","year":"2013","unstructured":"Dogan M.I.; Tasci I.; Bulucu F.; Abdominal obesity is associated with a lower ankle-brachial index in women with polycystic ovary syndrome. Angiology 2013,64(2),105-111","journal-title":"Angiology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1210\/jc.2011-1677","volume":"96","author":"Schmidt J.","year":"2011","unstructured":"Schmidt J.; Landin-Wilhelmsen K.; Br\u00e4nnstr\u00f6m M.; Dahlgren E.; Cardiovascular disease and risk factors in PCOS women of postmenopausal age: A 21-year controlled follow-up study. J Clin Endocrinol Metab 2011,96(12),3794-3803","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0895-4356(98)00035-3","volume":"51","author":"Pierpoint T.","year":"1998","unstructured":"Pierpoint T.; McKeigue P.M.; Isaacs A.J.; Wild S.H.; Jacobs H.S.; Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998,51(7),581-586","journal-title":"J Clin Epidemiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"dmad015","DOI":"10.1093\/humupd\/dmad015","author":"Mill\u00e1n-de-Meer M.","year":"2023","unstructured":"Mill\u00e1n-de-Meer M.; Luque-Ram\u00edrez M.; Nattero-Ch\u00e1vez L.; Escobar-Morreale H.F.; PCOS during the menopausal transition and after meno-pause: A systematic review and meta-analysis. Hum Reprod Update 2023,dmad015","journal-title":"Hum Reprod Update"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"8464","DOI":"10.1038\/ncomms9464","volume":"6","author":"Day F.R.","year":"2015","unstructured":"Day F.R.; Hinds D.A.; Tung J.Y.; Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun 2015,6(1),8464","journal-title":"Nat Commun"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.maturitas.2016.07.006","volume":"92","author":"Laven J.S.E.","year":"2016","unstructured":"Laven J.S.E.; Visser J.A.; Uitterlinden A.G.; Vermeij W.P.; Hoeijmakers J.H.J.; Menopause: Genome stability as new paradigm. Maturitas 2016,92,15-23","journal-title":"Maturitas"},{"key":"ref=76","first-page":"614","volume":"58","author":"Krysiak R.","year":"2006","unstructured":"Krysiak R.; Okopie\u0144 B.; Gdula-Dymek A.; Herman Z.S.; Update on the management of polycystic ovary syndrome. Pharmacol Rep 2006,58(5),614-625","journal-title":"Pharmacol Rep"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3390\/biomedicines10081989","volume":"10","author":"Jensterle M.","year":"2022","unstructured":"Jensterle M.; Herman R.; Jane\u017e A.; Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: From current clini-cal evidence to future perspectives. Biomedicines 2022,10(8),1989","journal-title":"Biomedicines"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"CD007506","DOI":"10.1002\/14651858.CD007506.pub4","volume":"2019","author":"Lim S.S.","year":"2019","unstructured":"Lim S.S.; Hutchison S.K.; Van Ryswyk E.; Norman R.J.; Teede H.J.; Moran L.J.; Lifestyle changes in women with polycystic ovary syndrome. Cochrane Libr 2019,2019(3),CD007506","journal-title":"Cochrane Libr"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13643-019-0962-3","volume":"8","author":"Kite C.","year":"2019","unstructured":"Kite C.; Lahart I.M.; Afzal I.; Exercise, or exercise and diet for the management of polycystic ovary syndrome: A systematic review and meta-analysis. Syst Rev 2019,8(1),51","journal-title":"Syst Rev"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/20420188221127142","author":"Abdalla M.A.","year":"2022","unstructured":"Abdalla M.A.; Shah N.; Deshmukh H.; Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: A systematic review and meta-analysis of randomised controlled trials. Ther Adv Endocrinol Metab 2022,13","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/jog.15301","volume":"48","author":"Miao K.","year":"2022","unstructured":"Miao K.; Zhou H.; Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta\u2010analysis. J Obstet Gynaecol Res 2022,48(7),1806-1815","journal-title":"J Obstet Gynaecol Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","volume":"105","author":"Cena H.","year":"2020","unstructured":"Cena H.; Chiovato L.; Nappi R.E.; Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab 2020,105(8),e2695-e2709","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/obr.12720","volume":"19","author":"Wang F.F.","year":"2018","unstructured":"Wang F.F.; Wu Y.; Zhu Y.H.; Pharmacologic therapy to induce weight loss in women who have obesity\/overweight with polycystic ovary syndrome: A systematic review and network meta-analysis. Obes Rev 2018,19(10),1424-1445","journal-title":"Obes Rev"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"Marso S.P.","year":"2016","unstructured":"Marso S.P.; Daniels G.H.; Brown-Frandsen K.; Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016,375(4),311-322","journal-title":"N Engl J Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12902-015-0005-6","volume":"15","author":"Kahal H.","year":"2015","unstructured":"Kahal H.; Aburima A.; Ungvari T.; The effects of treatment with liraglutide on atherothrombotic risk in obese young women with poly-cystic ovary syndrome and controls. BMC Endocr Disord 2015,15(1),14","journal-title":"BMC Endocr Disord"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EC-16-0113","volume":"6","author":"Nylander M.","year":"2017","unstructured":"Nylander M.; Fr\u00f8ssing S.; Kistorp C.; Faber J.; Skouby S.O.; Liraglutide in polycystic ovary syndrome: A randomized trial, investigating effects on thrombogenic potential. Endocr Connect 2017,6(2),89-99","journal-title":"Endocr Connect"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fendo.2019.00189","volume":"10","author":"Dawson A.J.","year":"2019","unstructured":"Dawson A.J.; Sathyapalan T.; Vince R.; The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syn-drome. Front Endocrinol 2019,10,189","journal-title":"Front Endocrinol"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"340","DOI":"10.23736\/S0391-1977.17.02609-8","volume":"42","author":"Papadakis G.","year":"2017","unstructured":"Papadakis G.; Kandaraki E.; Papalou O.; Vryonidou A.; Diamanti-Kandarakis E.; Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinol 2017,42(4),340-355","journal-title":"Minerva Endocrinol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","volume":"7","author":"Srivastava G.","year":"2018","unstructured":"Srivastava G.; Apovian C.; Future pharmacotherapy for obesity: New anti-obesity drugs on the horizon. Curr Obes Rep 2018,7(2),147-161","journal-title":"Curr Obes Rep"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/1570161121666230516141319","volume":"21","author":"Poredo\u0161 P.","year":"2023","unstructured":"Poredo\u0161 P.; Schernthaner G.H.; Blinc A.; Endocrine disorders and peripheral arterial disease: A series of reviews. Curr Vasc Pharmacol 2023,21(3),147-148","journal-title":"Curr Vasc Pharmacol"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611269146230920073301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/221464\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611269146230920073301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T13:50:23Z","timestamp":1705672223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/221464\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115701611269146230920073301","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}